Mind Medicine (MindMed) Inc. (E:MMED)
Business Focus: Biotechnology & Medical Research (NEC)
Apr 02, 2024 07:00 am ET
MindMed to Present at Upcoming April Medical Conferences
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (Cboe Canada: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it will present posters describing the impact that COVID has had on the epidemiology of Generalized Anxiety Disorder at two upcoming medical conferences:
Apr 01, 2024 05:00 pm ET
MindMed Announces Voluntary Delisting from Cboe Canada
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (Cboe Canada: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it has elected to voluntarily delist its common shares from Cboe Canada, effective at the close of markets on April 10, 2024, and the notice of voluntary delisting has been accepted by Cboe Canada. MindMed’s common shares will continue to be listed and tradable on The Nasdaq Global Select Market (“Nasdaq”) under the symbol “MNMD” and Canadian shareholders can continue to
Mar 11, 2024 07:00 am ET
MindMed to Participate in the Leerink Partners 2024 Global Biopharma Conference
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (Cboe Canada: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company’s management team will host one on one investor meetings at the Leerink Partners 2024 Global Biopharma Conference, which will be held in Miami, FL from March 11-13, 2024.
Mar 07, 2024 07:13 am ET
Mind Medicine (MindMed) Inc. Announces Pricing of Underwritten Offering of Common Shares and Concurrent Private Placement
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (Cboe Canada: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the pricing of an underwritten offering of 16,666,667 common shares, no par value per share, at an offering price of $6.00 per common share. In addition, the Company has entered into share purchase agreements for a concurrent private placement of 12,500,000 common shares at a price of $6.00 per common share. All of the common shares are being sold by MindMed. Gross pro
Mar 07, 2024 06:00 am ET
MindMed Receives FDA Breakthrough Therapy Designation and Announces Positive 12-Week Durability Data From Phase 2B Study of MM120 for Generalized Anxiety Disorder
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (Cboe Canada MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that FDA has granted breakthrough designation to its MM120 (lysergide d-tartrate) program for the treatment of generalized anxiety disorder (GAD). The Company also announced that its Phase 2b study of MM120 in GAD met its key secondary endpoint, and 12-week topline data demonstrated clinically and statistically significant durability of activity observed through Week
Mar 01, 2024 09:00 am ET
MindMed to Host Conference Call and Webcast to Discuss Data Update for MM120
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (Cboe Canada: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it will host a conference call and webcast on March 7, 2024. The program will provide an update on MM120 in Generalized Anxiety Disorder (GAD), including 12-week topline safety, efficacy, and durability results from the Company’s Phase 2b trial and results from the Company’s Phase 1 pharmacokinetics bridging trial to support the advancement of the MM120 oral dissolving
Feb 28, 2024 07:05 am ET
MindMed Reports 2023 Financial Results and Business Updates
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (Cboe Canada:MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced its financial results for the year ended December 31, 2023 and provided a business update.
Feb 22, 2024 07:00 am ET
MindMed to Host Conference Call and Webcast to Discuss 2023 Financial Results and Provide Business Update
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (Cboe Canada: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it plans to host a conference call on Wednesday, February 28, 2024, at 8:00 a.m. ET to provide a corporate update and review the Company’s results for the year ended December 31, 2023.
Feb 07, 2024 07:00 am ET
MindMed to Participate in the 34th Annual Oppenheimer Healthcare Life Sciences Conference
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (Cboe Canada: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company’s management team will participate in the 34th Annual Oppenheimer Healthcare Life Sciences Conference:
Jan 08, 2024 07:45 am ET
MindMed Announces Business Update and Anticipated Milestones for 2024
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today provided a corporate update and outlook for 2024.
Dec 14, 2023 07:30 am ET
MindMed Announces Positive Topline Results from Phase 2b Trial of MM-120 in Generalized Anxiety Disorder
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced positive topline results from its Phase 2b clinical trial of MM-120 (lysergide d-tartrate) in generalized anxiety disorder (GAD). The trial met its primary endpoint, with MM-120 demonstrating statistically significant and clinically meaningful dose-dependent improvements on the Hamilton Anxiety rating scale (HAM-A) compared to placebo at Week 4. MM-120 was administered as a
Nov 02, 2023 04:01 pm ET
MindMed Reports Third Quarter 2023 Financial Results and Business Highlights
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today reported its financial results for the quarter ended September 30, 2023.
Oct 26, 2023 07:30 am ET
MindMed to Host Conference Call and Webcast to Discuss Third Quarter 2023 Financial Results and Provide Business Update
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it plans to host a conference call on Thursday, November 2, 2023, at 4:30 p.m. ET to provide a corporate update and review the Company’s results for the quarter ended September 30, 2023.
Oct 24, 2023 07:30 am ET
MindMed Completes Enrollment of Phase 2a Trial of MM-120 in Adults with Attention-Deficit/Hyperactivity Disorder (ADHD)
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it has completed enrollment of Study MMED007, the Company’s Phase 2a study evaluating repeated low-dose administration of MM-120 (lysergide D-tartrate) for the treatment of adults with ADHD.
Oct 03, 2023 07:30 am ET
MindMed to Present Data on the Preclinical Activity of MM-402 at the 36th Annual European College of Neuropsychopharmacology (ECNP) Congress
Mind Medicine (MindMed) Inc (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today the upcoming presentation of preclinical data of MM-402, the Company’s proprietary form of the R-enantiomer of 3,4-Methylenedioxymethamphetamine (“MDMA”), in a model for autism spectrum disorder (“ASD”) at the 36th Annual ECNP Congress that is being held in Barcelona, Spain from October 7-10, 2023. The Company plans to initiate its first clinical trial of MM-402 in
Sep 14, 2023 07:30 am ET
MindMed to Participate in the TD Cowen 3rd Annual Novel Mechanisms in Neuropsychiatry Summit
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that Robert Barrow, Chief Executive Officer of MindMed, will participate in a panel at the TD Cowen 3rd Annual Novel Mechanisms in Neuropsychiatry Summit on Wednesday, September 20, 2023 at 11:00 a.m. ET, which is being hosted virtually. The webcast of the panel discussion will be accessible to those registered to attend the summit.
Sep 12, 2023 07:30 am ET
MindMed Completes Enrollment of Phase 2b Trial of MM-120 in Generalized Anxiety Disorder (GAD)
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it has completed enrollment and dosing in Study MMED008, the Company’s Phase 2b study evaluating MM-120 (lysergide D-tartrate) for the treatment of GAD.
Aug 28, 2023 07:30 am ET
MindMed to Participate at September Investor Conferences
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company’s management team will participate in the following investor conferences:
Aug 14, 2023 07:30 am ET
MindMed Secures $50.0 Million Credit Facility with K2 HealthVentures
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it has entered into a senior secured credit facility with K2 HealthVentures, a healthcare-focused specialty finance company.
Aug 03, 2023 04:01 pm ET
MindMed Reports Second Quarter 2023 Financial Results and Business Highlights
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today reported its financial results for the quarter ended June 30, 2023.
Aug 03, 2023 07:30 am ET
MindMed Announces Exclusive License Agreement With Catalent for Its Patented Zydis® Fast-Dissolve Technology for Use with MM-120
Mind Medicine (MindMed) Inc (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it has entered into a license agreement with Catalent, a leader in enabling the development and supply of better treatments for patients worldwide, to access Catalent’s proprietary Zydis® orally disintegrating tablet (ODT) technology.
Jul 31, 2023 08:30 am ET
MindMed to Host Conference Call and Webcast to Discuss Second Quarter 2023 Financial Results and Provide Business Update
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or "MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it plans to host a conference call on Thursday, August 3, 2023, at 4:30 p.m. ET to provide a corporate update and review the Company’s results for the quarter ended June 30, 2023.
Jun 22, 2023 08:30 am ET
MindMed to Participate in the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company’s management team will participate in the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference:
Jun 21, 2023 12:08 pm ET
MindMed Announces Election of All Six Company Nominees at Annual Meeting
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), today announced that, based upon a preliminary vote assessment, shareholders have elected all six of the Company’s nominees – CEO Robert Barrow, Dr. Suzanne Bruhn, Dr. Roger Crystal, David Gryska, Andreas Krebs and Carol A. Vallone – to the Board of Directors (the “Board”) at the Annual Meeting of Shareholders (the "Meeting") held today.
Jun 20, 2023 08:30 am ET
MindMed Provides Overview of Clinical Progress and Corporate Updates at Investor Day
Mind Medicine (MindMed) Inc (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, will provide an overview of clinical progress and corporate updates during an Investor Day today focused primarily on the MM-120 (lysergide D-tartrate) program in generalized anxiety disorder (GAD).
Jun 15, 2023 10:45 am ET
MindMed Adjourns Annual General Meeting of Shareholders
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), today announced that the Company’s Annual General Meeting of Shareholders (the “Meeting”) on June 15, 2023 was convened at 10:00 a.m. (Eastern Time) and adjourned, without any business being conducted, due to lack of the required quorum. The Meeting will resume with respect to all proposals at 10:00 a.m. (Eastern Time) on Wednesday, June 21, 2023 and will continue to be held virtually via live webcast at
Jun 09, 2023 09:00 am ET
MindMed Urges Shareholders to Vote TODAY for Company Nominees Ahead of June 13th Deadline
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”) today urged shareholders to vote FOR the election of all six of MindMed’s highly qualified director candidates to the Board of Directors (the “Board”) in advance of the Annual Meeting of Shareholders scheduled for June 15, 2023.
Jun 08, 2023 11:30 am ET
Leading Proxy Advisory Firm Glass Lewis Recommends MindMed Shareholders Vote FOR All Six Company Nominees
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”) today announced that leading proxy advisory firm Glass, Lewis & Co. (“Glass Lewis”) recommends shareholders vote for the election of ALL of MindMed’s six highly qualified director nominees to the Board of Directors (the “Board”) at the upcoming Annual Meeting of Shareholders (“Annual Meeting”), scheduled for June 15, 2023. Previously, leading proxy advisory firm Institutional Shareholder Services Inc. (“ISS”) also recommended in favor of all six of the Company’s director nominees.
Jun 07, 2023 08:00 am ET
MindMed to Host Investor Day June 2023
Mind Medicine (MindMed) Inc (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that its management team will a host an Analyst Day in New York City on Tuesday, June 20th, 2023 that will focus on the MM-120 program in generalized anxiety disorder (GAD). In person attendance is by invitation only. All others are invited to participate via the live webcast.
Jun 05, 2023 07:00 am ET
Cedar Clinical Research, by Numinus, the top enrolling clinical research site for MindMed's Phase 2B study evaluating MM-120
VANCOUVER, BC, June 5, 2023 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, is pleased to announce Cedar Clinical Research (CCR) is a top research site for MindMed's Phase 2b study evaluating MM-120 (lysergide D-tartrate) for General Anxiety Disorder.
Jun 05, 2023 07:00 am ET
Cedar Clinical Research, by Numinus, the top enrolling clinical research site for MindMed's Phase 2B study evaluating MM-120
VANCOUVER, BC, June 5, 2023 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, is pleased to announce Cedar Clinical Research (CCR) is a top research site for MindMed's Phase 2b study evaluating MM-120 (lysergide D-tartrate) for General Anxiety Disorder.
Jun 01, 2023 07:00 am ET
MindMed to Participate at Upcoming Investor Conferences
Mind Medicine (MindMed) Inc (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company’s management team will participate in the following investor conferences:
May 25, 2023 04:00 pm ET
MindMed Releases Investor Presentation Highlighting How the Company is Unlocking the Power of Psychedelics for Patients and Shareholders
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”) today announced that it has released an investor presentation in connection with its 2023 Annual Meeting of Shareholders. The presentation details how under the guidance of MindMed’s world-class Board of Directors the Company is executing against a well-defined plan to create value – with two Phase 2 clinical readouts for lead product candidate MM-120 (LSD D-tartrate) expected in late 2023. MindMed urges all shareholders to vote "FOR" the Company's six highly qualified director nominees using the
May 25, 2023 08:00 am ET
MindMed Publishes Report by Leading FDA Experts Validating MindMed’s MM-120 Drug Development Strategy
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that the Company has published a report by Greenleaf Health, Inc. (“Greenleaf”) setting forth an independent expert regulatory assessment of MindMed’s MM-120 (lysergide D-tartrate) development strategy. The analysis – led by the former Director and Deputy Director of the Office of New Drugs at the U.S. Food and Drug Administration (“FDA”) – focuses on MindMed’s clinical and regulato
May 24, 2023 07:00 am ET
MindMed to Present Data on the Preclinical Activity of MM-402 at the American Society of Clinical Psychopharmacology (ASCP) 2023 Annual Meeting
Mind Medicine (MindMed) Inc (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today the upcoming presentation of preclinical data of MM-402, the Company’s proprietary form of the R-enantiomer of 3,4-Methylenedioxymethamphetamine (“MDMA”), in a model for autism spectrum disorder (“ASD”) at the ASCP 2023 Annual Meeting that is being held in Miami Beach, FL from May 30-June 2, 2023. The Company plans to initiate its first clinical trial of MM-402 in 2023.
May 17, 2023 04:01 pm ET
MindMed Announces Enrollment Milestone in Phase 2b Trial of MM-120 in Generalized Anxiety Disorder (GAD)
Mind Medicine (MindMed) Inc (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that the company’s Phase 2b study evaluating MM-120 (lysergide D-tartrate) for GAD is over 50% enrolled and dosed. The trial plans to enroll up to 200 participants who will receive a single administration of 25 µg, 50 µg, 100 µg or 200 µg of MM-120 or placebo. Topline results are expected to be announced in late 2023.
May 04, 2023 04:02 pm ET
MindMed Reports First Quarter 2023 Financial Results and Business Highlights
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today reported its financial results for the quarter ended March 31, 2023.
May 02, 2023 08:00 am ET
MindMed Sends Letter to Shareholders Highlighting Company’s Positive Momentum and Value-Enhancing Strategy
The Board of Directors (the “Board”) of Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today sent a letter to shareholders highlighting the importance of voting at its upcoming 2023 Annual Meeting of Shareholders (the “Annual Meeting”). By voting for the Board’s nominees, shareholders can support the significant progress that has been made under the current Board to achieve MindMed’s mission to deliver on the therapeutic potential of psychedeli
May 01, 2023 04:01 pm ET
MindMed to Host Conference Call and Webcast to Discuss First Quarter 2023 Financial Results and Provide Business Update
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or "MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it plans to host a conference call on Thursday, May 4, 2023, at 4:30 p.m. ET to provide a corporate update and review the Company’s results for the quarter ended March 31, 2023.
Apr 26, 2023 07:00 am ET
MindMed to Participate in May Investor Conferences
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company’s management team will participate in the following investor conferences:
Apr 18, 2023 04:15 pm ET
MindMed Files Preliminary Proxy Statement for 2023 Annual Meeting
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it has filed its preliminary proxy materials with the U.S. Securities and Exchange Commission (“SEC”) in connection with the 2023 Annual General Meeting of Shareholders (the “Annual Meeting”), which has not yet been scheduled.
Apr 14, 2023 07:00 am ET
MindMed Collaborators Announce Positive Topline Data from Phase 2 Trial of Lysergide (LSD) in Major Depressive Disorder (MDD)
Mind Medicine (MindMed) Inc (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, announced today that Prof. Matthias Liechti and Dr. Felix Mueller, MindMed collaborators at University Hospital Basel (UHB) and the University Hospital of Psychiatry, have released positive topline data from a double-blind, investigator-initiated trial evaluating lysergide in the treatment of MDD. These findings were presented on April 14, 2023 in Basel, Switzerland.
Apr 13, 2023 07:00 am ET
MindMed Appoints Mark R. Sullivan as Chief Legal Officer and Corporate Secretary
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Mark R. Sullivan, effective today, as Chief Legal Officer and Corporate Secretary.
Mar 09, 2023 04:02 pm ET
MindMed Reports Full Year 2022 Financial Results and Business Highlights
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today reported its financial results for the full-year ended December 31, 2022.
Feb 28, 2023 07:30 am ET
MindMed to Participate in March Investor Conferences
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that members of the Company's management team will participate in the following investor conferences:
Jan 09, 2023 06:30 am ET
MindMed Provides Corporate Update and 2023 Outlook
- Company positioned for key MM-120 Phase 2b data readout in GAD and Phase 2a data readout in ADHD in late 2023
Jan 09, 2023 06:30 am ET
MindMed Provides Corporate Update and 2023 Outlook
- Company positioned for key MM-120 Phase 2b data readout in GAD and Phase 2a data readout in ADHD in late 2023
Dec 01, 2022 06:30 am ET
MindMed to Participate in the Canaccord Genuity New Paradigms and Treatment Approaches in Mental Health Conference
NEW YORK, Dec. 1, 2022 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that members of the Company's management team will participate in Canaccord Genuity's New Paradigms and Treatment Approaches in Mental Health Conference.
Dec 01, 2022 06:30 am ET
MindMed to Participate in the Canaccord Genuity New Paradigms and Treatment Approaches in Mental Health Conference
NEW YORK, Dec. 1, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that members of the Company's management team will participate in Canaccord Genuity's New Paradigms and Treatment Approaches in Mental Health Conference.
Nov 11, 2022 06:30 am ET
MindMed to Participate in the Jefferies London Healthcare Conference
NEW YORK, Nov. 11, 2022 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that members of the Company's management team will participate in the Jefferies London Healthcare Conference, taking place in London, UK from November 15-17, 2022.
Nov 11, 2022 06:30 am ET
MindMed to Participate in the Jefferies London Healthcare Conference
NEW YORK, Nov. 11, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that members of the Company's management team will participate in the Jefferies London Healthcare Conference, taking place in London, UK from November 15-17, 2022.
Nov 10, 2022 07:05 am ET
MindMed Reports Third Quarter 2022 Financial Results and Business Highlights
– Initiated Phase 2b dose-optimization trial in patients with Generalized Anxiety Disorder, with first patients dosed in Q3 2022 and key clinical readout expected in late 2023 –
Nov 10, 2022 07:05 am ET
MindMed Reports Third Quarter 2022 Financial Results and Business Highlights
– Initiated Phase 2b dose-optimization trial in patients with Generalized Anxiety Disorder, with first patients dosed in Q3 2022 and key clinical readout expected in late 2023 –
Nov 03, 2022 07:30 am ET
MindMed to Host Earnings Call to Discuss Third Quarter 2022 Financial Results and Provide Business Update
NEW YORK, Nov. 3, 2022 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that it will host its earnings call on Thursday, November 10, 2022, at 8:30 a.m. EDT to discuss its financial results for the quarter ended September 30, 2022 and provide a business update.
Nov 03, 2022 07:30 am ET
MindMed to Host Earnings Call to Discuss Third Quarter 2022 Financial Results and Provide Business Update
NEW YORK, Nov. 3, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that it will host its earnings call on Thursday, November 10, 2022, at 8:30 a.m. EDT to discuss its financial results for the quarter ended September 30, 2022 and provide a business update.
Oct 05, 2022 08:35 am ET
MindMed to Participate in the Cantor Fitzgerald Neurology & Psychiatry Conference
NEW YORK, Oct. 5, 2022 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that members of MindMed's management team will participate in the Cantor Fitzgerald Neurology & Psychiatry Conference, taking place at the Ritz Carlton, San Francisco, CA from October 6-7, 2022.
Oct 05, 2022 08:35 am ET
MindMed to Participate in the Cantor Fitzgerald Neurology & Psychiatry Conference
NEW YORK, Oct. 5, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that members of MindMed's management team will participate in the Cantor Fitzgerald Neurology & Psychiatry Conference, taking place at the Ritz Carlton, San Francisco, CA from October 6-7, 2022.
Oct 04, 2022 07:30 am ET
MindMed Collaborators Initiate Phase 1 Comparative PK/PD Trial of R-, S- and Racemic MDMA
- Study will compare the acute subjective, physiological, and endocrine effects of R-MDMA, S-MDMA, and racemic MDMA in 24 healthy subjects -
Oct 04, 2022 07:30 am ET
MindMed Collaborators Initiate Phase 1 Comparative PK/PD Trial of R-, S- and Racemic MDMA
- Study will compare the acute subjective, physiological, and endocrine effects of R-MDMA, S-MDMA, and racemic MDMA in 24 healthy subjects -
Sep 27, 2022 11:47 pm ET
MindMed Announces Pricing of Public Offering of Common Shares and Warrants
NEW YORK, Sept. 27, 2022 /CNW/ -- Mind Medicine (MindMed) Inc. ("MindMed") (NASDAQ: MNMD) (NEO: MMED), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced the pricing of its underwritten public offering of 7,058,823 common shares, together with accompanying warrants to purchase 7,058,823 common shares. The combined offering price to the public of each common share and accompanying warrant is $4.25. Each common share will be sold in combination with an accompanying warrant, and each warrant is exercisable to purchase one common
Sep 27, 2022 11:47 pm ET
MindMed Announces Pricing of Public Offering of Common Shares and Warrants
NEW YORK, Sept. 27, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. ("MindMed") (NASDAQ: MNMD) (NEO: MMED), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced the pricing of its underwritten public offering of 7,058,823 common shares, together with accompanying warrants to purchase 7,058,823 common shares. The combined offering price to the public of each common share and accompanying warrant is $4.25. Each common share will be sold in combination with an accompanying warrant, and each warrant is exercisable to purchase one
Sep 27, 2022 04:17 pm ET
MindMed Announces Proposed Public Offering of Common Shares
NEW YORK, Sept. 27, 2022 /CNW/ -- Mind Medicine (MindMed) Inc. ("MindMed") (Nasdaq: MNMD) (NEO: MMED), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that it intends to offer and sell, subject to market conditions, common shares with accompanying warrants to purchase common shares in an underwritten public offering. All of the securities to be sold in the offering will be offered by MindMed. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or
Sep 27, 2022 04:17 pm ET
MindMed Announces Proposed Public Offering of Common Shares
NEW YORK, Sept. 27, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. ("MindMed") (Nasdaq: MNMD) (NEO: MMED), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that it intends to offer and sell, subject to market conditions, common shares with accompanying warrants to purchase common shares in an underwritten public offering. All of the securities to be sold in the offering will be offered by MindMed. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be complet
Sep 20, 2022 07:30 am ET
MindMed Collaborators Dose First Patient in Phase 1 Investigator-Initiated Trial of MDMA-Like Substances
First-in-human trial to investigate the tolerability, pharmacology, and pharmacokinetics of novel MDMA-like compounds versus a placebo in healthy subjectsAcute effects of equivalent doses will be compared across the following compounds: MDMA, MDA, Lys-MDMA and Lys-MDANEW YORK, Sept. 20, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced the first patient has been dosed in a Phase 1 investigator-initiated study led by M
Sep 20, 2022 07:30 am ET
MindMed Collaborators Dose First Patient in Phase 1 Investigator-Initiated Trial of MDMA-Like Substances
First-in-human trial to investigate the tolerability, pharmacology, and pharmacokinetics of novel MDMA-like compounds versus a placebo in healthy subjectsAcute effects of equivalent doses will be compared across the following compounds: MDMA, MDA, Lys-MDMA and Lys-MDANEW YORK, Sept. 20, 2022 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced the first patient has been dosed in a Phase 1 investigator-initiated study led by MindMed
Sep 14, 2022 07:30 am ET
MindMed Announces Compliance with Nasdaq Listing Requirements
NEW YORK, Sept. 14, 2022 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that it has received a letter from The Nasdaq Stock Market LLC advising the Company that it has regained compliance with Nasdaq's minimum bid price listing requirement. The Company has satisfied the terms for continued listing on the Nasdaq Capital Market by complying with the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5550(
Sep 14, 2022 07:30 am ET
MindMed Announces Compliance with Nasdaq Listing Requirements
NEW YORK, Sept. 14, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that it has received a letter from The Nasdaq Stock Market LLC advising the Company that it has regained compliance with Nasdaq's minimum bid price listing requirement. The Company has satisfied the terms for continued listing on the Nasdaq Capital Market by complying with the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rul
Sep 08, 2022 07:30 am ET
MindMed Announces Positive Results from Collaborators' Placebo-Controlled Investigator-Initiated Trial Published in Peer-Reviewed Journal
- Data from University Hospital Basel (UHB) study supports the clinical development of MindMed's proprietary MM-120 product candidate for Generalized Anxiety Disorder ("GAD") –
Sep 08, 2022 07:30 am ET
MindMed Announces Positive Results from Collaborators' Placebo-Controlled Investigator-Initiated Trial Published in Peer-Reviewed Journal
- Data from University Hospital Basel (UHB) study supports the clinical development of MindMed's proprietary MM-120 product candidate for Generalized Anxiety Disorder ("GAD") –
Sep 07, 2022 07:30 am ET
MindMed to Participate in H.C. Wainwright Global Investment Conference
NEW YORK, Sept. 7, 2022 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that it will participate virtually at the H.C. Wainwright 24th Annual Global Investment Conference, and its presentation will be available beginning at 7:00 a.m. ET on September 12, 2022.
Sep 07, 2022 07:30 am ET
MindMed to Participate in H.C. Wainwright Global Investment Conference
NEW YORK, Sept. 7, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that it will participate virtually at the H.C. Wainwright 24th Annual Global Investment Conference, and its presentation will be available beginning at 7:00 a.m. ET on September 12, 2022.
Aug 26, 2022 04:30 pm ET
MindMed Completes 1-for-15 Reverse Share Split
- Common shares will begin trading on a split-adjusted basis at market open on August 29, 2022 -
Aug 26, 2022 04:30 pm ET
MindMed Completes 1-for-15 Reverse Share Split
- Common shares will begin trading on a split-adjusted basis at market open on August 29, 2022 -
Aug 25, 2022 07:30 am ET
MindMed Announces First Patient Dosed in Phase 2b Trial of MM-120 in Generalized Anxiety Disorder
NEW YORK, Aug. 25, 2022 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED) (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced first patient dosing in its Phase 2b dose-optimization trial of MM-120, a pharmaceutically optimized form of lysergic acid diethylamide (LSD), for the treatment of Generalized Anxiety Disorder (GAD).
Aug 25, 2022 07:30 am ET
MindMed Announces First Patient Dosed in Phase 2b Trial of MM-120 in Generalized Anxiety Disorder
NEW YORK, Aug. 25, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED) (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced first patient dosing in its Phase 2b dose-optimization trial of MM-120, a pharmaceutically optimized form of lysergic acid diethylamide (LSD), for the treatment of Generalized Anxiety Disorder (GAD).
Aug 23, 2022 09:59 am ET
IIROC Trade Resumption - MMED
TORONTO, Aug. 23, 2022 /CNW/ - Trading resumes in:
Aug 23, 2022 09:50 am ET
IIROC Trading Halt - MMED
TORONTO, Aug. 23, 2022 /CNW/ - The following issues have been halted by IIROC:
Aug 12, 2022 07:30 am ET
MindMed Strengthens Board with Appointment of Two New Independent Directors
NEW YORK, Aug. 12, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced the appointment of Dr. Suzanne Bruhn and Dr. Roger Crystal, effective August 11, 2022 as independent members of its Board of Directors.
Aug 12, 2022 07:30 am ET
MindMed Strengthens Board with Appointment of Two New Independent Directors
NEW YORK, Aug. 12, 2022 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced the appointment of Dr. Suzanne Bruhn and Dr. Roger Crystal, effective August 11, 2022 as independent members of its Board of Directors.
Aug 11, 2022 04:06 pm ET
MindMed Reports Second Quarter 2022 Financial Results and Business Highlights
– Phase 2b dose-optimization trial in patients with General Anxiety Disorder underway with first patient dosing expected in Q3 2022 –
Aug 11, 2022 04:06 pm ET
MindMed Reports Second Quarter 2022 Financial Results and Business Highlights
– Phase 2b dose-optimization trial in patients with General Anxiety Disorder underway with first patient dosing expected in Q3 2022 –
Aug 04, 2022 05:30 pm ET
MindMed Board of Directors Approves Reverse Share Split
NEW YORK, Aug. 4, 2022 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that its Board of Directors has approved a ratio of 1-for-15 reverse share split of its common shares. As a result of the reverse share split, there will be approximately 28.4 million shares of common shares issued and outstanding1. Post reverse share split, the common shares will continue to trade under the symbols "MNMD" on the Nasdaq and "MMED" on the Neo
Aug 04, 2022 05:30 pm ET
MindMed Board of Directors Approves Reverse Share Split
NEW YORK, Aug. 4, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that its Board of Directors has approved a ratio of 1-for-15 reverse share split of its common shares. As a result of the reverse share split, there will be approximately 28.4 million shares of common shares issued and outstanding1. Post reverse share split, the common shares will continue to trade under the symbols "MNMD" on the Nasdaq and "MMED" on
Aug 04, 2022 07:30 am ET
MindMed to Host Earnings Call to Discuss Second Quarter 2022 Financial Results and Provide Business Update
NEW YORK, Aug. 4, 2022 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that it will host its earnings call on Thursday, August 11, 2022, at 4:30 p.m. EDT to discuss its financial results for the quarter ended June 30, 2022 and provide a business update.
Aug 04, 2022 07:30 am ET
MindMed to Host Earnings Call to Discuss Second Quarter 2022 Financial Results and Provide Business Update
NEW YORK, Aug. 4, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that it will host its earnings call on Thursday, August 11, 2022, at 4:30 p.m. EDT to discuss its financial results for the quarter ended June 30, 2022 and provide a business update.
Aug 02, 2022 07:30 am ET
MindMed to Participate in the Canaccord Genuity 42nd Annual Growth Conference
NEW YORK, Aug. 2, 2022 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that members of MindMed's management team will participate in the Canaccord Genuity 42nd Annual Growth Conference, to be held in Boston, MA, August 8-11, 2022.
Aug 02, 2022 07:30 am ET
MindMed to Participate in the Canaccord Genuity 42nd Annual Growth Conference
NEW YORK, Aug. 2, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that members of MindMed's management team will participate in the Canaccord Genuity 42nd Annual Growth Conference, to be held in Boston, MA, August 8-11, 2022.
Jun 30, 2022 05:30 pm ET
MindMed Announces Completion of Share Redesignation
NEW YORK, June 30, 2022 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED) ("MindMed'' or the "Company") announces that it has completed its previously announced redesignation of its subordinate voting shares as common shares (the "Common Shares") of the Company. The Common Shares will be assigned CUSIP number 60255C802 and ISIN number CA60255C8025 following the redesignation. The Common Shares will begin trading on a post-Redesignation basis under the new CUSIP and ISIN numbers on the NEO Exchange and NASDAQ at market open on July 4, 2022 and July 5, 2022, respectively, under
Jun 01, 2022 05:30 pm ET
Mindmed Announces Voting Results for Annual General and Special Meeting
NEW YORK, June 1, 2022 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), announces the voting results of the Company's annual general and special meeting of shareholders held on June 1, 2022 (the "Meeting").
Jun 01, 2022 05:30 pm ET
Mindmed Announces Voting Results for Annual General and Special Meeting
NEW YORK, June 1, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), announces the voting results of the Company's annual general and special meeting of shareholders held on June 1, 2022 (the "Meeting").
Jun 01, 2022 07:59 am ET
MindMed to Participate in the Jefferies Global Healthcare Conference
NEW YORK, June 1, 2022 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that Robert Barrow, Chief Executive Officer and Director, will participate in the Jefferies Global Healthcare Conference, to be held in New York, NY from June 8-10, 2022.
Jun 01, 2022 07:59 am ET
MindMed to Participate in the Jefferies Global Healthcare Conference
NEW YORK, June 1, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that Robert Barrow, Chief Executive Officer and Director, will participate in the Jefferies Global Healthcare Conference, to be held in New York, NY from June 8-10, 2022.
May 23, 2022 07:30 am ET
MindMed Appoints Schond L. Greenway as Chief Financial Officer
NEW YORK, May 23, 2022 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED) (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, announced the appointment of Schond L. Greenway as Chief Financial Officer. Mr. Greenway comes to MindMed with over 20 years of experience in investment banking, finance and corporate advisory, and investment analysis in the life sciences sector.
May 23, 2022 07:30 am ET
MindMed Appoints Schond L. Greenway as Chief Financial Officer
NEW YORK, May 23, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED) (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, announced the appointment of Schond L. Greenway as Chief Financial Officer. Mr. Greenway comes to MindMed with over 20 years of experience in investment banking, finance and corporate advisory, and investment analysis in the life sciences sector.
May 19, 2022 07:30 am ET
MindMed Reports Topline Data From Phase 1 Trial of MM-110 in Development for the Treatment of Opioid Withdrawal
- Positive safety and tolerability results support the advancement of MM-110 and guide the Phase 2a dose design in individuals undergoing supervised opioid withdrawal -
May 19, 2022 07:30 am ET
MindMed Reports Topline Data From Phase 1 Trial of MM-110 in Development for the Treatment of Opioid Withdrawal
- Positive safety and tolerability results support the advancement of MM-110 and guide the Phase 2a dose design in individuals undergoing supervised opioid withdrawal -
May 16, 2022 09:36 pm ET
MindMed Announces At-The-Market Offering
NEW YORK, May 16, 2022 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED) (the "Company"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, announced today that the registration statement on Form S-3, filed on May 4, 2022, was declared effective by the U.S. Securities and Exchange Commission, which includes a prospectus for an at-the-market equity offering under which the Company may offer and sell its Subordinate Voting Shares or common shares re-designated from the Company's Subordinate Voting Shares (collectively, the "sh
May 16, 2022 07:30 am ET
MindMed Reports First Quarter 2022 Financial Results and Business Highlights
- Advanced clinical programs for three lead drug candidates -
May 16, 2022 07:30 am ET
MindMed Reports First Quarter 2022 Financial Results and Business Highlights
- Advanced clinical programs for three lead drug candidates -
May 12, 2022 07:30 am ET
MindMed to Host Key Opinion Leader Webinar on Substance Use Disorders and Withdrawal Management
- Webinar to feature presentations from Kelly E. Dunn, PhD, MBA, and Stuart Gitlow, MD, MPH, MBA, on Thursday, May 19 at 11:00am EDT -
May 12, 2022 07:30 am ET
MindMed to Host Key Opinion Leader Webinar on Substance Use Disorders and Withdrawal Management
- Webinar to feature presentations from Kelly E. Dunn, PhD, MBA, and Stuart Gitlow, MD, MPH, MBA, on Thursday, May 19 at 11:00am EDT -
May 11, 2022 07:30 am ET
MindMed Collaborators Prof. Liechti and Dr. Holze Announce Positive Topline Data from Phase 2 Trial Evaluating LSD in Anxiety Disorders
- Results from the placebo-controlled investigator-initiated trial, conducted at the University Hospital Basel (UHB), demonstrate the significant, long-lasting beneficial effects of LSD and potential to safely mitigate symptoms of anxiety and depression -
May 11, 2022 07:30 am ET
MindMed Collaborators Prof. Liechti and Dr. Holze Announce Positive Topline Data from Phase 2 Trial Evaluating LSD in Anxiety Disorders
- Results from the placebo-controlled investigator-initiated trial, conducted at the University Hospital Basel (UHB), demonstrate the significant, long-lasting beneficial effects of LSD and potential to safely mitigate symptoms of anxiety and depression -
May 09, 2022 07:30 am ET
MindMed to Host Earnings Call to Discuss First Quarter 2022 Financial Results and Provide Business Update
NEW YORK, May 9, 2022 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that it will host its earnings call on Monday, May 16, 2022, at 8:30 a.m. EDT to discuss its financial results for the quarter ended March 31, 2022 and provide a business update.
May 09, 2022 07:30 am ET
MindMed to Host Earnings Call to Discuss First Quarter 2022 Financial Results and Provide Business Update
NEW YORK, May 9, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that it will host its earnings call on Monday, May 16, 2022, at 8:30 a.m. EDT to discuss its financial results for the quarter ended March 31, 2022 and provide a business update.
Apr 14, 2022 07:30 am ET
MindMed Collaborator Dr. Matthias Liechti to Present Topline Clinical Trial Results for LSD in Anxiety Disorders at PSYCH Symposium
- "LSD as a Treatment for Anxiety Disorders: New Evidence of Efficacy" will present the most recent and robust data on LSD in patients with anxiety -
Apr 05, 2022 07:30 am ET
MindMed Appoints Francois Lilienthal, MD as Chief Commercial Officer
- Dr. Lilienthal brings over 20 years of global biopharmaceutical experience, leading the development and commercialization of innovative medicines across multiple therapeutic areas including psychiatry and neurology -
Mar 29, 2022 09:23 pm ET
MindMed Reports Proposed Change in Auditor for 2022 Fiscal Year
NEW YORK, March 29, 2022 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED) (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, reported a change in auditor for the 2022 fiscal year, subject to the approval of the Company's shareholders at the Company's 2022 annual general and special meeting.
Mar 28, 2022 07:30 am ET
MindMed Reports Full Year 2021 Financial Results and Business Highlights
- FDA cleared MindMed's Investigational New Drug (IND) application for Phase 2b dose optimization trial of MM-120 -
Mar 28, 2022 07:30 am ET
MindMed Reports Full Year 2021 Financial Results and Business Highlights
- FDA cleared MindMed's Investigational New Drug (IND) application for Phase 2b dose optimization trial of MM-120 -
Mar 25, 2022 05:30 pm ET
MindMed Announces Transition of CFO
NEW YORK, March 25, 2022 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED) (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that its Chief Financial Officer, David Guebert, will be retiring from his position on March 31, 2022.
Mar 25, 2022 05:30 pm ET
MindMed Announces Transition of CFO
NEW YORK, March 25, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED) (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that its Chief Financial Officer, David Guebert, will be retiring from his position on March 31, 2022.
Mar 21, 2022 07:30 am ET
MindMed to Host Earnings Call to Discuss Full-Year 2021 Financial Results and Provide Business Update
NEW YORK, March 21, 2022 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that it will host its earnings call on Monday, March 28, 2022, at 8:30 a.m. EDT to discuss its financial results for the full year ended December 31, 2021 and provide a business update.
Mar 21, 2022 07:30 am ET
MindMed to Host Earnings Call to Discuss Full-Year 2021 Financial Results and Provide Business Update
NEW YORK, March 21, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that it will host its earnings call on Monday, March 28, 2022, at 8:30 a.m. EDT to discuss its financial results for the full year ended December 31, 2021 and provide a business update.
Mar 09, 2022 06:30 am ET
MindMed to Participate in March Investor Conferences
NEW YORK, March 9, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), a clinical-stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that Robert Barrow, Chief Executive Officer and Director, will participate in the following upcoming investor conferences in March:
Mar 02, 2022 06:30 am ET
MindMed Announces Publication of Study Comparing the Acute Effects of Lysergic Acid Diethylamide and Psilocybin in Healthy Subjects
NEW YORK, March 2, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), a clinical-stage biopharmaceutical company developing psychedelic-inspired therapies for the treatment of brain-based disorders, today announced the peer-reviewed publication of a study directly comparing the acute effects of Lysergic Acid Diethylamide (LSD) and psilocybin in healthy subjects. The data, published in Neuropsychopharmacology and titled, "Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subject
Feb 23, 2022 06:30 am ET
MindMed Converts Multiple Voting Shares to Subordinate Voting Shares
- Automatic conversion to be effective March 14, 2022 -
Feb 23, 2022 06:30 am ET
MindMed Converts Multiple Voting Shares to Subordinate Voting Shares
- Automatic conversion to be effective March 14, 2022 -
Jan 25, 2022 06:30 am ET
FDA Clears MindMed IND for MM-120 in Treatment of Generalized Anxiety Disorder
NEW YORK, Jan. 25, 2022 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a clinical-stage biopharmaceutical company developing psychedelic-inspired therapies for the treatment of brain-based disorders, announced today that the U.S. Food and Drug Administration (FDA) has cleared MindMed's Investigational New Drug (IND) application, allowing the Company's Phase 2b dose-optimization trial of MM-120 for the treatment of generalized anxiety disorder (GAD) to proceed.
Jan 18, 2022 06:30 am ET
MindMed Enrolls First Participant in a Study of its Session Monitoring System
NEW YORK, Jan. 18, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a clinical-stage biopharmaceutical company developing psychedelic-inspired therapies for the treatment of mental health and addiction, today announced that it has enrolled the first subjects into its Session Monitoring System (SMS-01) study evaluating the passive collection of sensory data during a consciousness-altering therapeutic session. SMS-01 utilizes MindMed's Session Monitoring System (MSMS), which it believes could have therapeutic applications in the treatmen
Jan 18, 2022 06:30 am ET
MindMed Enrolls First Participant in a Study of its Session Monitoring System
NEW YORK, Jan. 18, 2022 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a clinical-stage biopharmaceutical company developing psychedelic-inspired therapies for the treatment of mental health and addiction, today announced that it has enrolled the first subjects into its Session Monitoring System (SMS-01) study evaluating the passive collection of sensory data during a consciousness-altering therapeutic session. SMS-01 utilizes MindMed's Session Monitoring System (MSMS), which it believes could have therapeutic applications in the treatment of ps
Jan 17, 2022 10:02 am ET
IIROC Trade Resumption - MMED
TORONTO, Jan. 17, 2022 /CNW/ - Trading resumes in:
Jan 17, 2022 09:55 am ET
IIROC Trading Halt - MMED
TORONTO, Jan. 17, 2022 /CNW/ - The following issues have been halted by IIROC:
Jan 07, 2022 03:30 pm ET
Stephen Hurst Resigns from MindMed Board of Directors
NEW YORK, Jan. 7, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-derived therapies, announces the resignation of Stephen Hurst from his role as a Director of the Company's Board of Directors.
Jan 07, 2022 03:30 pm ET
Stephen Hurst Resigns from MindMed Board of Directors
NEW YORK, Jan. 7, 2022 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-derived therapies, announces the resignation of Stephen Hurst from his role as a Director of the Company's Board of Directors.
Jan 04, 2022 06:30 am ET
MindMed Successfully Completes Phase 1 Clinical Trial of 18-MC
- Last subject completed study in late 2021 with topline results expected in early 2022 -
Jan 04, 2022 06:30 am ET
MindMed Successfully Completes Phase 1 Clinical Trial of 18-MC
- Last subject completed study in late 2021 with topline results expected in early 2022 -
Dec 30, 2021 06:30 am ET
MindMed to Participate at the LifeSci Partners 11th Annual Corporate Access Event
NEW YORK, Dec. 30, 2021 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, today announced that MindMed's Chief Executive Officer and Director, Robert Barrow, will be participating in a panel and in one-on-one investor meetings at the LifeSci Partners 11th Annual Corporate Access Event, to be held virtually January 5-7, 2022.
Dec 30, 2021 06:30 am ET
MindMed to Participate at the LifeSci Partners 11th Annual Corporate Access Event
NEW YORK, Dec. 30, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, today announced that MindMed's Chief Executive Officer and Director, Robert Barrow, will be participating in a panel and in one-on-one investor meetings at the LifeSci Partners 11th Annual Corporate Access Event, to be held virtually January 5-7, 2022.
Dec 29, 2021 06:30 am ET
MindMed Announces Transitions to Management Team
- Bradford Cross, Chief Technology Officer to transition; Don Gehlert, PhD, Chief Scientific Officer to transition to Senior Scientific Advisor -
Dec 29, 2021 06:30 am ET
MindMed Announces Transitions to Management Team
- Bradford Cross, Chief Technology Officer to transition; Don Gehlert, PhD, Chief Scientific Officer to transition to Senior Scientific Advisor -
Dec 21, 2021 06:30 am ET
MindMed Provides Status Update on IND for Phase 2b Trial of LSD for the Treatment of Generalized Anxiety Disorder
- FDA has issued a clinical hold on initial IND submission required to initiate Phase 2b trial of LSD for the treatment of generalized anxiety disorder -
Dec 21, 2021 06:30 am ET
MindMed Provides Status Update on IND for Phase 2b Trial of LSD for the Treatment of Generalized Anxiety Disorder
- FDA has issued a clinical hold on initial IND submission required to initiate Phase 2b trial of LSD for the treatment of generalized anxiety disorder -
Dec 17, 2021 06:30 am ET
MindMed Initiates Phase 2a LSD Trial for the Treatment of Adult ADHD
- Enrolling patients in proof-of-concept exploratory trial conducted in collaboration with the University Hospital Basel in Switzerland and Maastricht University in the Netherlands –
Dec 17, 2021 06:30 am ET
MindMed Initiates Phase 2a LSD Trial for the Treatment of Adult ADHD
- Enrolling patients in proof-of-concept exploratory trial conducted in collaboration with the University Hospital Basel in Switzerland and Maastricht University in the Netherlands –
Dec 14, 2021 06:30 am ET
MindMed Appoints Robert Barrow as Chief Executive Officer and Director
-Mr. Barrow previously served as interim Chief Executive Officer and Chief Development Officer of MindMed
Dec 14, 2021 06:30 am ET
MindMed Appoints Robert Barrow as Chief Executive Officer and Director
-Mr. Barrow previously served as interim Chief Executive Officer and Chief Development Officer of MindMed
Dec 09, 2021 06:30 am ET
MindMed Engages in Productive Pre-Submission Meeting with FDA for Development of the MindMed Session Monitoring System
NEW YORK, Dec. 9, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies recently met with the United States Food and Drug Administration (FDA) Center for Devices and Radiological Health (CDRH) with consultation from the Center for Drug Evaluation and Research (CDER) concerning several key points for ongoing development of the MindMed Session Monitoring System (MSMS) in a device pre-submission meeting that took place on October 25, 2021.
Dec 09, 2021 06:30 am ET
MindMed Engages in Productive Pre-Submission Meeting with FDA for Development of the MindMed Session Monitoring System
NEW YORK, Dec. 9, 2021 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies recently met with the United States Food and Drug Administration (FDA) Center for Devices and Radiological Health (CDRH) with consultation from the Center for Drug Evaluation and Research (CDER) concerning several key points for ongoing development of the MindMed Session Monitoring System (MSMS) in a device pre-submission meeting that took place on October 25, 2021.
Dec 02, 2021 06:30 am ET
MindMed to Participate at the Benzinga Global Small Cap Conference
NEW YORK, Dec. 2, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, today announced that MindMed's Chief Executive Officer, Robert Barrow, will provide a corporate update and the Company's management will participate in one-on-one investor meetings at the Benzinga Global Small Cap Conference to be held virtually on December 8-9, 2021.
Dec 02, 2021 06:30 am ET
MindMed to Participate at the Benzinga Global Small Cap Conference
NEW YORK, Dec. 2, 2021 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, today announced that MindMed's Chief Executive Officer, Robert Barrow, will provide a corporate update and the Company's management will participate in one-on-one investor meetings at the Benzinga Global Small Cap Conference to be held virtually on December 8-9, 2021.
Dec 01, 2021 06:30 am ET
MindMed to Present at H.C. Wainwright 2nd Annual Psychedelics Conference
NEW YORK, Dec. 1, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, today announced that MindMed's Chief Executive Officer, Robert Barrow, will participate in a panel and Company's management will participate in one-on-one investor meetings at the virtual H.C. Wainwright 2nd Annual Psychedelics Conference to be held on Monday, December 6, 2021.
Dec 01, 2021 06:30 am ET
MindMed to Present at H.C. Wainwright 2nd Annual Psychedelics Conference
NEW YORK, Dec. 1, 2021 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, today announced that MindMed's Chief Executive Officer, Robert Barrow, will participate in a panel and Company's management will participate in one-on-one investor meetings at the virtual H.C. Wainwright 2nd Annual Psychedelics Conference to be held on Monday, December 6, 2021.
Nov 30, 2021 06:30 am ET
MindMed and Liechti Lab publish first human data on the interacting effects of an SSRI and psilocybin
NEW YORK, Nov. 30, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ); (the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce the publication of the first data on the interaction of the selective serotonin uptake inhibitor (SSRI) escitalopram with the acute response to psilocybin in humans. The publication resulted from a randomized, double-blind, placebo-controlled, crossover pharmacology study in healthy volunteers conducted by the University Hospital Basel Liechti Lab and sponsored by MindMed.
Nov 30, 2021 06:30 am ET
MindMed and Liechti Lab publish first human data on the interacting effects of an SSRI and psilocybin
NEW YORK, Nov. 30, 2021 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ); (the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce the publication of the first data on the interaction of the selective serotonin uptake inhibitor (SSRI) escitalopram with the acute response to psilocybin in humans. The publication resulted from a randomized, double-blind, placebo-controlled, crossover pharmacology study in healthy volunteers conducted by the University Hospital Basel Liechti Lab and sponsored by MindMed.
Nov 16, 2021 06:30 am ET
MindMed Launches Study of Low-Dose LSD Effects on Sleep and Cognitive Measures
NEW YORK, Nov. 16, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD; NEO: MMED; DE: MMQ; the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce it has launched recruitment for a randomized placebo-controlled study evaluating the effects of daytime and evening administration of repeated low doses of LSD (the "LSD Study").
Nov 16, 2021 06:30 am ET
MindMed Launches Study of Low-Dose LSD Effects on Sleep and Cognitive Measures
NEW YORK, Nov. 16, 2021 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD; NEO: MMED; DE: MMQ; the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce it has launched recruitment for a randomized placebo-controlled study evaluating the effects of daytime and evening administration of repeated low doses of LSD (the "LSD Study").
Nov 15, 2021 06:30 am ET
MindMed Announces Financial Results for the Third Quarter 2021 and Business Highlights; Cash Balance of $145.9 USD ($185.4 CAD) to Execute on Diverse Clinical Pipeline
NEW YORK, Nov. 15, 2021 /PRNewswire/ -- MindMed (Nasdaq: MNMD, NEO: MMED, DE: MMQ), a leading biotech company developing psychedelic-inspired therapies, has announced its quarterly financial results for the quarter ended September 30, 2021.
Nov 15, 2021 06:30 am ET
MindMed Announces Financial Results for the Third Quarter 2021 and Business Highlights; Cash Balance of $145.9 USD ($185.4 CAD) to Execute on Diverse Clinical Pipeline
NEW YORK, Nov. 15, 2021 /CNW/ -- MindMed (Nasdaq: MNMD, NEO: MMED, DE: MMQ), a leading biotech company developing psychedelic-inspired therapies, has announced its quarterly financial results for the quarter ended September 30, 2021.
Nov 12, 2021 06:30 am ET
MindMed to Present at the Jefferies London Healthcare Conference
NEW YORK, Nov. 12, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce that its CEO, Robert Barrow, will be speaking at Jefferies 2021 London Healthcare Conference, taking place on November 16-19. Management will be available during the conference for in-person and virtual one-on-one meetings.
Nov 12, 2021 06:30 am ET
MindMed to Present at the Jefferies London Healthcare Conference
NEW YORK, Nov. 12, 2021 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce that its CEO, Robert Barrow, will be speaking at Jefferies 2021 London Healthcare Conference, taking place on November 16-19. Management will be available during the conference for in-person and virtual one-on-one meetings.
Nov 05, 2021 07:30 am ET
MindMed Appoints Dr. Maria Oquendo to its Scientific Advisory Board
NEW YORK, Nov. 5, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce the appointment of Maria A. Oquendo, M.D., Ph.D. to its Scientific Advisory Board.
Nov 05, 2021 07:30 am ET
MindMed Appoints Dr. Maria Oquendo to its Scientific Advisory Board
NEW YORK, Nov. 5, 2021 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce the appointment of Maria A. Oquendo, M.D., Ph.D. to its Scientific Advisory Board.
Nov 01, 2021 07:30 am ET
MindMed to Present at Web Summit on Future of Mental Health
NEW YORK, Nov. 1, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce that CEO Robert Barrow will be speaking at Web Summit, taking place on November 1-4, 2021 in Lisbon, Portugal.
Nov 01, 2021 07:30 am ET
MindMed to Present at Web Summit on Future of Mental Health
NEW YORK, Nov. 1, 2021 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce that CEO Robert Barrow will be speaking at Web Summit, taking place on November 1-4, 2021 in Lisbon, Portugal.
Oct 26, 2021 07:00 am ET
MindMed Expands its Drug Development Pipeline with Launch of R(-)-MDMA Program
NEW YORK, Oct. 26, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED), (DE: MMQ); the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce an expansion of its pipeline with the launch of a program to develop R(-)-MDMA for the treatment of social anxiety and functioning in diagnoses that include Autism Spectrum Disorder (ASD). This program represents a significant expansion and diversification of MindMed's pipeline and furthers the Company's mission to bring innovative products to benefit patients and address unmet
Oct 26, 2021 07:00 am ET
MindMed Expands its Drug Development Pipeline with Launch of R(-)-MDMA Program
NEW YORK, Oct. 26, 2021 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED), (DE: MMQ); the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce an expansion of its pipeline with the launch of a program to develop R(-)-MDMA for the treatment of social anxiety and functioning in diagnoses that include Autism Spectrum Disorder (ASD). This program represents a significant expansion and diversification of MindMed's pipeline and furthers the Company's mission to bring innovative products to benefit patients and address unmet medical
Oct 25, 2021 07:30 am ET
MindMed CMO to Chair Digital Biomarkers Summit
NEW YORK, Oct. 25, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce that Chief Medical Officer Daniel R Karlin, MD MA, will chair The Digital Biomarkers & Digital Measurements Summit, held virtually on October 26 - 27, 2021.
Oct 25, 2021 07:30 am ET
MindMed CMO to Chair Digital Biomarkers Summit
NEW YORK, Oct. 25, 2021 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce that Chief Medical Officer Daniel R Karlin, MD MA, will chair The Digital Biomarkers & Digital Measurements Summit, held virtually on October 26 - 27, 2021.
Oct 13, 2021 07:30 am ET
MindMed Joins Clinical Trials Transformation Initiative
NEW YORK, Oct. 13, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, has joined the Clinical Trials Transformation Initiative (CTTI) to contribute in developing and driving adoption of practices that increase the quality and efficiency of clinical trials.
Oct 13, 2021 07:30 am ET
MindMed Joins Clinical Trials Transformation Initiative
NEW YORK, Oct. 13, 2021 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, has joined the Clinical Trials Transformation Initiative (CTTI) to contribute in developing and driving adoption of practices that increase the quality and efficiency of clinical trials.
Oct 05, 2021 07:30 am ET
MindMed Announces Strategic Research Collaboration with Sphere Health
NEW YORK, Oct. 5, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, has agreed to partner with Sphere Health – a physician-founded employee benefits provider targeting treatments for people with severe mental illness – to collect and analyze multimodal data in order to improve the understanding of a variety of biomarkers associated with mental illnesses including anxiety and affective disorders.
Oct 05, 2021 07:30 am ET
MindMed Announces Strategic Research Collaboration with Sphere Health
NEW YORK, Oct. 5, 2021 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, has agreed to partner with Sphere Health – a physician-founded employee benefits provider targeting treatments for people with severe mental illness – to collect and analyze multimodal data in order to improve the understanding of a variety of biomarkers associated with mental illnesses including anxiety and affective disorders.
Sep 30, 2021 07:30 am ET
MindMed Announces Appointment of Andreas Krebs and Carol Vallone as Directors and Transition of Bruce Linton
NEW YORK, Sept. 30, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) ("MindMed" or the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce that its board of directors has appointed Mr. Andreas Krebs and Ms. Carol Vallone as directors of the Company, effective immediately.
Sep 30, 2021 07:30 am ET
MindMed Announces Appointment of Andreas Krebs and Carol Vallone as Directors and Transition of Bruce Linton
NEW YORK, Sept. 30, 2021 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) ("MindMed" or the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce that its board of directors has appointed Mr. Andreas Krebs and Ms. Carol Vallone as directors of the Company, effective immediately.
Sep 29, 2021 07:30 am ET
MindMed Appoints University of North Carolina Psychiatrist and Pharmacologist Dr. Bryan Roth to Scientific Advisory Board
NEW YORK, Sept. 29, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce the addition of Bryan L. Roth, MD, PhD to its Scientific Advisory Board.
Sep 29, 2021 07:30 am ET
MindMed Appoints University of North Carolina Psychiatrist and Pharmacologist Dr. Bryan Roth to Scientific Advisory Board
NEW YORK, Sept. 29, 2021 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce the addition of Bryan L. Roth, MD, PhD to its Scientific Advisory Board.
Sep 28, 2021 07:30 am ET
MindMed to present at the Benzinga Healthcare Small Cap Conference
NEW YORK, Sept. 28, 2021 /PRNewswire/ -- (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce that Robert Barrow, Chief Executive Officer of MindMed, will be speaking at the Benzinga Healthcare Small Cap Conference, taking place on September 29-30, 2021.
Sep 28, 2021 07:30 am ET
MindMed to present at the Benzinga Healthcare Small Cap Conference
NEW YORK, Sept. 28, 2021 /CNW/ -- (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce that Robert Barrow, Chief Executive Officer of MindMed, will be speaking at the Benzinga Healthcare Small Cap Conference, taking place on September 29-30, 2021.
Sep 23, 2021 07:30 am ET
MindMed and Liechti Lab Provide Results from their Psilocybin R&D Collaboration
NEW YORK, Sept. 23, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce that Dr. Matthias Liechti presented data from several ongoing studies at the INSIGHT Conference in Berlin, Germany. These investigator-initiated studies are being conducted as part of MindMed's ongoing collaboration with the UHB Liechti Lab.
Sep 21, 2021 07:30 am ET
MindMed Announces Participation at Upcoming Investor Conferences
NEW YORK, Sept. 21, 2021 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, today announces that Robert Barrow, Chief Executive Officer of MindMed, will participate in the following investor conferences:
Sep 21, 2021 07:30 am ET
MindMed Announces Participation at Upcoming Investor Conferences
NEW YORK, Sept. 21, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, today announces that Robert Barrow, Chief Executive Officer of MindMed, will participate in the following investor conferences:
Sep 10, 2021 07:30 am ET
MindMed to Present at H.C. Wainwright 23rd Annual Global Investment Conference
NEW YORK, Sept. 10, 2021 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce that Robert Barrow, Chief Executive Officer of MindMed, will present at the virtual H.C. Wainwright 23rd Annual Global Investment Conference taking place September 13-15, 2021. Members of management will also be available to speak with institutional investors in one-on-one virtual meetings throughout the conference.
Sep 10, 2021 07:30 am ET
MindMed to Present at H.C. Wainwright 23rd Annual Global Investment Conference
NEW YORK, Sept. 10, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce that Robert Barrow, Chief Executive Officer of MindMed, will present at the virtual H.C. Wainwright 23rd Annual Global Investment Conference taking place September 13-15, 2021. Members of management will also be available to speak with institutional investors in one-on-one virtual meetings throughout the conference.
Sep 09, 2021 07:30 am ET
MindMed to Attend 8th Annual "Mobile in Clinical Trials" Conference
NEW YORK, Sept. 9, 2021 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce that its Chief Medical Officer, Daniel R. Karlin, MD MA, will co-chair the 8th annual Mobile in Clinical Trials Conference, which will be held virtually on September 27, 2021 and is a partner program to the 2021 DPharm Conference.
Sep 09, 2021 07:30 am ET
MindMed to Attend 8th Annual "Mobile in Clinical Trials" Conference
NEW YORK, Sept. 9, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce that its Chief Medical Officer, Daniel R. Karlin, MD MA, will co-chair the 8th annual Mobile in Clinical Trials Conference, which will be held virtually on September 27, 2021 and is a partner program to the 2021 DPharm Conference.
Sep 02, 2021 07:30 am ET
MindMed and BioXcel Therapeutics Publish an International Patent Application Describing a System for Identifying Agitation Episodes
NEW YORK, Sept. 2, 2021 /CNW/ -- MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, and BioXcel Therapeutics, Inc. ("BioXcel"), a leading clinical-stage biopharmaceutical company, announce the publication of BioXcel's International Patent Application No. PCT/US2020/051256 (published as WO2021055595) for detecting and preventing the early onset of agitation in patients predisposed to highly agitated behaviour. The disclosure provides a method for measuring the signs of an impending agitation event and alerts the c
Sep 02, 2021 07:30 am ET
MindMed and BioXcel Therapeutics Publish an International Patent Application Describing a System for Identifying Agitation Episodes
NEW YORK, Sept. 2, 2021 /PRNewswire/ -- MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, and BioXcel Therapeutics, Inc. ("BioXcel"), a leading clinical-stage biopharmaceutical company, announce the publication of BioXcel's International Patent Application No. PCT/US2020/051256 (published as WO2021055595) for detecting and preventing the early onset of agitation in patients predisposed to highly agitated behaviour. The disclosure provides a method for measuring the signs of an impending agitation event and alert
Aug 24, 2021 07:30 am ET
MindMed Announces Collaboration With Forian To Advance Development Of Personalized Psychiatry For Anxiety Disorders
NEW YORK, Aug. 24, 2021 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, has agreed to work with Forian Inc. (NASDAQ: FORA), a leading provider of evidence-based support for more comprehensive clinical and commercial decision-making.
Aug 24, 2021 07:30 am ET
MindMed Announces Collaboration With Forian To Advance Development Of Personalized Psychiatry For Anxiety Disorders
NEW YORK, Aug. 24, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, has agreed to work with Forian Inc. (NASDAQ: FORA), a leading provider of evidence-based support for more comprehensive clinical and commercial decision-making.
Aug 17, 2021 07:30 am ET
MindMed Joins Critical Path Institute's Patient-Reported Outcome Consortium
NEW YORK, Aug. 17, 2021 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, has joined the Critical Path Institute's ("C-Path's") Patient-Reported Outcome (PRO) Consortium to assist in the development of new approaches to advance medical innovation and regulatory science.
Aug 17, 2021 07:30 am ET
MindMed Joins Critical Path Institute's Patient-Reported Outcome Consortium
NEW YORK, Aug. 17, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, has joined the Critical Path Institute's ("C-Path's") Patient-Reported Outcome (PRO) Consortium to assist in the development of new approaches to advance medical innovation and regulatory science.
Aug 12, 2021 11:50 pm ET
MindMed Announces 2021 Q2 Financial Results; Cash Balance of $157 USD Million ($195 CAD Million) to Execute on Diverse Clinical Pipeline
NEW YORK, Aug. 12, 2021 /CNW/ -- MindMed (Nasdaq: MNMD), (NEO: MMED), (DE: MMQ), a leading biotech company developing psychedelic-inspired therapies, has announced its quarterly financial results for the quarter ended June 30, 2021.
Aug 12, 2021 11:50 pm ET
MindMed Announces 2021 Q2 Financial Results; Cash Balance of $157 USD Million ($195 CAD Million) to Execute on Diverse Clinical Pipeline
NEW YORK, Aug. 12, 2021 /PRNewswire/ -- MindMed (Nasdaq: MNMD), (NEO: MMED), (DE: MMQ), a leading biotech company developing psychedelic-inspired therapies, has announced its quarterly financial results for the quarter ended June 30, 2021.
Aug 10, 2021 07:30 am ET
MindMed Appoints Dr. Robert Dworkin to Scientific Advisory Board
NEW YORK, Aug. 10, 2021 /CNW/ -- MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), a leading biotech company developing psychedelic-inspired therapies, announces the addition of Robert H. Dworkin, Ph.D. to its Scientific Advisory Board.
Aug 10, 2021 07:30 am ET
MindMed Appoints Dr. Robert Dworkin to Scientific Advisory Board
NEW YORK, Aug. 10, 2021 /PRNewswire/ -- MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), a leading biotech company developing psychedelic-inspired therapies, announces the addition of Robert H. Dworkin, Ph.D. to its Scientific Advisory Board.
Aug 03, 2021 07:30 am ET
MindMed Joins Digital Medicine Society to Improve Health Outcomes and Equity Using Technology
NEW YORK, Aug. 3, 2021 /CNW/ -- MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), a leading biotech company developing psychedelic-inspired therapies, announced today that it will participate in and financially support the Digital Medicine Society's (DiMe) Digital Health Measurement Collaborative Community (DATAcc), an effort to develop best practices and streamline the medical field's approaches to measuring health using digital technologies.
Aug 03, 2021 07:30 am ET
MindMed Joins Digital Medicine Society to Improve Health Outcomes and Equity Using Technology
NEW YORK, Aug. 3, 2021 /PRNewswire/ -- MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), a leading biotech company developing psychedelic-inspired therapies, announced today that it will participate in and financially support the Digital Medicine Society's (DiMe) Digital Health Measurement Collaborative Community (DATAcc), an effort to develop best practices and streamline the medical field's approaches to measuring health using digital technologies.
Jul 28, 2021 07:00 am ET
MindMed Announces Initiation of Phase 1 Clinical Trial of Intravenous DMT
NEW YORK, July 28, 2021 /CNW/ -- MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce the start of a Phase 1 clinical trial to assess the safety, pharmacokinetics and pharmacodynamics of DMT, a naturally occurring psychedelic substance and an active ingredient in ayahuasca. The outcome of this Phase 1 clinical trial is expected to facilitate potential future Phase 2 clinical trials of DMT in patients. The clinical trial is being conducted as an investigator-initiated study by Dr. Matthias Liechti as part of
Jul 28, 2021 07:00 am ET
MindMed Announces Initiation of Phase 1 Clinical Trial of Intravenous DMT
NEW YORK, July 28, 2021 /PRNewswire/ -- MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce the start of a Phase 1 clinical trial to assess the safety, pharmacokinetics and pharmacodynamics of DMT, a naturally occurring psychedelic substance and an active ingredient in ayahuasca. The outcome of this Phase 1 clinical trial is expected to facilitate potential future Phase 2 clinical trials of DMT in patients. The clinical trial is being conducted as an investigator-initiated study by Dr. Matthias Liechti as p
Jul 12, 2021 07:30 am ET
MindMed Chosen to Participate in Cowen's Psychedelics & Novel Mechanisms in Neuropsychiatry Virtual Summit
NEW YORK, July 12, 2021 /CNW/ -- MindMed (NASDAQ: MNMD, NEO: MMED, DE: MMQ), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce that MindMed's Chief Executive Officer, Robert Barrow, will be leading a roundtable discussion at Cowen's Psychedelics & Novel Mechanisms in Neuropsychiatry Virtual Summit.
Jul 12, 2021 07:30 am ET
MindMed Chosen to Participate in Cowen's Psychedelics & Novel Mechanisms in Neuropsychiatry Virtual Summit
NEW YORK, July 12, 2021 /PRNewswire/ -- MindMed (NASDAQ: MNMD, NEO: MMED, DE: MMQ), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce that MindMed's Chief Executive Officer, Robert Barrow, will be leading a roundtable discussion at Cowen's Psychedelics & Novel Mechanisms in Neuropsychiatry Virtual Summit.
Jul 08, 2021 08:20 am ET
MindMed Announces Partnership with Datavant, a Leading Health Data Connectivity Company
NEW YORK, July 8, 2021 /CNW/ -- MindMed (Nasdaq: MNMD, NEO: MMED, DE: MMQ), a leading biotech company developing psychedelic-inspired therapies, and Datavant, Inc. ("Datavant"), a leader in helping healthcare organizations safely connect their data, announced a partnership through which MindMed will use Datavant's privacy-protecting technology to link MindMed's clinical trial data to external data from both clinical and real-world sources. MindMed plans to use Datavant's linking technology across various stages of the drug lifecycle including discovery, clinical development, and commerciali
Jul 08, 2021 08:20 am ET
MindMed Announces Partnership with Datavant, a Leading Health Data Connectivity Company
NEW YORK, July 8, 2021 /PRNewswire/ -- MindMed (Nasdaq: MNMD, NEO: MMED, DE: MMQ), a leading biotech company developing psychedelic-inspired therapies, and Datavant, Inc. ("Datavant"), a leader in helping healthcare organizations safely connect their data, announced a partnership through which MindMed will use Datavant's privacy-protecting technology to link MindMed's clinical trial data to external data from both clinical and real-world sources. MindMed plans to use Datavant's linking technology across various stages of the drug lifecycle including discovery, clinical development, and comm
Jun 28, 2021 07:30 am ET
MindMed Included in FTSE Russell 3000® Index
NEW YORK, June 28, 2021 /CNW/ -- MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), a leading psychedelic-inspired medicine company announced that effective Friday, June 25th, 2021, MindMed has been added to the FTSE Russell 3000® index which measures the performance of the largest 3,000 US companies.
Jun 28, 2021 07:30 am ET
MindMed Included in FTSE Russell 3000® Index
NEW YORK, June 28, 2021 /PRNewswire/ -- MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), a leading psychedelic-inspired medicine company announced that effective Friday, June 25th, 2021, MindMed has been added to the FTSE Russell 3000® index which measures the performance of the largest 3,000 US companies.
Jun 23, 2021 07:30 am ET
MindMed Appoints MGH Psychiatrist-in-Chief Dr. Maurizio Fava to Scientific Advisory Board
NEW YORK, June 23, 2021 /CNW/ -- MindMed (Nasdaq: MNMD) (NEO: MMED) (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, has announced the addition of Dr. Maurizio Fava, a world-leading expert in psychiatry and psychiatric clinical trials from Massachusetts General Hospital and the Harvard Medical School to the Company's Scientific Advisory Board.
Jun 23, 2021 07:30 am ET
MindMed Appoints MGH Psychiatrist-in-Chief Dr. Maurizio Fava to Scientific Advisory Board
NEW YORK, June 23, 2021 /PRNewswire/ -- MindMed (Nasdaq: MNMD) (NEO: MMED) (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, has announced the addition of Dr. Maurizio Fava, a world-leading expert in psychiatry and psychiatric clinical trials from Massachusetts General Hospital and the Harvard Medical School to the Company's Scientific Advisory Board.
Jun 17, 2021 07:30 am ET
MindMed Appoints Pharmaceutical Veteran Peter Bergethon, M.D. to Scientific Advisory Board
NEW YORK, June 17, 2021 /CNW/ -- MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, has announced the addition of Dr. Peter Bergethon, a world-leading expert in neurology, digital medicine, and central nervous system (CNS) drug development to the Company's Scientific Advisory Board.
Jun 17, 2021 07:30 am ET
MindMed Appoints Pharmaceutical Veteran Peter Bergethon, M.D. to Scientific Advisory Board
NEW YORK, June 17, 2021 /PRNewswire/ -- MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, has announced the addition of Dr. Peter Bergethon, a world-leading expert in neurology, digital medicine, and central nervous system (CNS) drug development to the Company's Scientific Advisory Board.
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Canadianinsider.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Read more...Insider information is based on filings made on the System
for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission.Read less
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Interactive technical study charts by TradingView. Copyright © 2024 INK Research Corp. All rights reserved. All trade-marks or trade names not owned by INK Research Corp. are the property of their respective owners.
